Compare Celestica Inc (CLS) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

CLS trades at $260.01, down 3.35% over 24 hours, with a bearish technical signal but strong fundamentals including revenue growth to $15.6B in 2026 and net income of $1.1B. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Analyst sentiment remains overwhelmingly positive with a 67.86% buy rating and a consensus price target of $456.23, indicating significant upside potential from current levels.

The outlook for CLS is favorable due to robust earnings momentum and analyst optimism, though near-term price volatility and insider selling pose risks. Investment appeal centers on its leadership in AI infrastructure and projected margin expansion, but investors should monitor competitive pressures and execution of growth initiatives.

Charles River Laboratories (CRL) trades at $345.37, up 1.68% on the day, with strong technical momentum as price approaches resistance near $348. The stock shows consistent earnings beats in recent quarters but faces fundamental challenges with negative net income margins (-5.96%) and elevated valuation multiples (P/E 684.85). Recent investor day highlighted strategic growth targets of 5-7% revenue growth and $300M savings by 2030.

While analyst sentiment remains bullish (73% buy ratings) and technicals suggest near-term strength, the stock trades above consensus price target ($308.36) with stretched valuations. Key risks include profitability challenges, NHP cost volatility, and execution risks on growth targets. The current price near 52-week highs requires careful risk management despite positive momentum.